← All trials
NCT04081077
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2019
- Primary completion
- Dec 30, 2020
- Completion date
- Mar 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 240
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medecins Sans FrontieresLead sponsor
- Drugs for Neglected Diseases InitiativeCollaborator
- ERT ClinicalCollaborator
- Government of BelarusCollaborator
- Government of UzbekistanCollaborator
- Medecins Sans FrontieresOverall official - principal investigator
- University of BaselCollaborator
- University of LiverpoolCollaborator
- World Health OrganizationCollaborator
- Global Alliance for TB Drug DevelopmentCollaborator
- University of California, San FranciscoCollaborator
- University of LondonCollaborator
- TB & HIV Investigative Network (THINK)Collaborator
- Republican Research and Practical Centre for Pulmonology and TuberculosisCollaborator
- Hackensack University Medical CenterCollaborator
- Wits Health Consortium (Pty) LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.